ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements with these filters
Panacea Biotec notified BSE and NSE of a board meeting on 14 November 2026 to approve provisional unaudited quarterly and half-year results. The trading window stays closed till 16 November 2026.
Panacea Biotec held its 42nd Annual General Meeting on September 29, 2026, where members considered and adopted various financial and operational business items.
Panacea Biotec received two Income Tax demand orders totaling ₹4.32 Crore for alleged income misreporting. The company disputes the demand and plans to file an appeal.
Panacea Biotec received four income tax demand orders totaling ₹9.82 Crore for alleged misreporting. The company contests this as non-maintainable and plans to appeal.
Panacea Biotec sent reminder letters to physical shareholders requesting PAN and KYC updates per SEBI circulars. No transaction or business event is involved.
Panacea Biotec Limited issued the notice for its 42nd Annual General Meeting scheduled for September 29, 2026, via video conferencing. Shareholders can participate through remote e-voting.
Panacea Biotec Limited has submitted its monthly share dematerialization report for August 2026. This is a routine regulatory compliance filing under SEBI Regulation 74(5).
Nosheen Sheikh, an employee's immediate relative, sold 3,000 equity shares of Panacea Biotec Ltd for ₹12.29 Lakh in a market sale.
Panacea Biotec Ltd reported revenue from operations of ₹199.6 Cr (+19.7% YoY) and net profit of ₹2.2 Cr (-45.0% YoY) for Q1 FY27.
Panacea Biotec will hold a board meeting on August 13, 2026, to approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
Panacea Biotec Ltd secured a Letter of Award from UNICEF worth approximately Rs.78.24 Crore ($8.205 million). The contract involves supplying bivalent Oral Polio Vaccine during 2028.
Panacea Biotec's subsidiary received a GST Show Cause Notice. The notice alleges a total tax liability of ₹4.06 Crore for FY 2022-23.
Panacea Biotec filed its quarterly shareholding pattern. The filing notes an off-market gift of 2,00,000 shares from Dr. Rajesh Jain to Rajesh Jain (HUF).
Panacea Biotec filed a High Court appeal against an industrial tribunal award involving 23 workmen. The court granted interim relief, preventing coercive steps against the company.
Rajesh Jain HUF acquired 200,000 shares of Panacea Biotec from Dr. Rajesh Jain by gift, increasing promoter holdings to 0.09%. No cash transaction was involved.
Panacea Biotec filed appeals against three tribunal awards and will challenge a fourth. The company believes the awards are challengeable and foresees no material financial impact.
Panacea Biotec joined the €11.1 million (₹120.90 Crore) EU-funded DENSTAR consortium. The 48-month project advances licensure of its DengiAll vaccine in sub-Saharan Africa.
Panacea Biotec promoter Dr. Rajesh Jain will gift 2,00,000 shares to Rajesh Jain HUF. This internal promoter transfer maintains aggregate shareholding without changing overall control.
Panacea Biotec Ltd reported revenue from operations of ₹166.8 Cr (+25.9% YoY) and a net loss of ₹1 Cr for Q4 FY26.
Panacea Biotec approved FY2026 audited financial results and skipped dividends due to losses. The board also appointed Rajinder Singh Manku as an Independent Director.
Panacea Biotec filed its FY2026 Annual Secretarial Compliance Report. The report notes a minor ₹0.02 Crore penalty for a prior dividend intimation delay.
Panacea Biotec announced director appointments at its material subsidiary, Panacea Biotec Pharma Limited. These leadership changes aim to strengthen governance and ensure ethical board practices.
Panacea Biotec scheduled a board meeting for May 29, 2026, to approve annual financial results. Directors will also consider potential dividend recommendations for the fiscal year.